C5a

Synonyms

Prepro-C5, CPAMD4, Complement C5, C3 And PZP-Like Alpha-2-Macroglobulin Domain-Containing Protein 4, C5D, Complement Component 5, C5a, Anaphylatoxin C5a Analog, C5a Anaphylatoxin, C5b, ECLZB, C5,

Description

Activation of C5 by a C5 convertase initiates the spontaneous assembly of the late complement components, C5-C9, into the membrane attack complex. C5b has a transient binding site for C6. The C5b-C6 complex is the foundation upon which the lytic complex is assembled.Derived from proteolytic degradation of complement C5, C5 anaphylatoxin is a mediator of local inflammatory process. Binding to the receptor C5AR1 induces a variety of responses including intracellular calcium release, contraction of smooth muscle, increased vascular permeability, and histamine release from mast cells and basophilic leukocytes. C5a is also a potent chemokine which stimulates the locomotion of polymorphonuclear leukocytes and directs their migration toward sites of inflammation.

KO Status

F0

Drug Information

Launched drugs: 17
Drugs in clinical trials: 2
Latest Research Phase:Approved

Drug Name

Code

Phase

Company

Indications

Clinical Trials

Ravulizumab

ALXN-1210, ALXN-1810

Approved

Alexion Pharmaceuticals Inc

Myasthenia Gravis, Hemoglobinuria, Paroxysmal, Glomerulonephritis, IGA, Coronavirus Disease 2019 (COVID-19), Thrombotic Microangiopathies, Atypical Hemolytic Uremic Syndrome, Respiratory Distress Syndrome, Adult, Lupus Nephritis, Neuromyelitis Optica, Pneumonia, Viral, Amyotrophic Lateral Sclerosis, Acute Lung Injury

Eculizumab

5G1-1, HAL-1, LEX-98, h-5G1.1

Approved

Alexion Pharmaceuticals

Myasthenia Gravis, Hemoglobinuria, Paroxysmal, Atypical Hemolytic Uremic Syndrome, Delayed Graft Function, Neuromyelitis Optica, Asthma

Zilucoplan

RA-101495, RA-101495-SC

Phase 3 Clinical

Ra Pharma

Myasthenia Gravis, Hemoglobinuria, Paroxysmal, Lupus Nephritis, Hemolytic-Uremic Syndrome

Avacincaptad pegol

ARC-187, ARC-1905

Phase 3 Clinical

Archemix

Geographic Atrophy, Stargardt Disease, Macular Degeneration

Vilobelimab

IFX-1, CaCP-29

Phase 3 Clinical

Beijing Mabworks Biotech Co Ltd, Inflarx

Shock, Septic, Granulomatosis with Polyangiitis, Pyoderma Gangrenosum, Microscopic Polyangiitis, Sepsis, Coronavirus Disease 2019 (COVID-19), Hidradenitis Suppurativa, Systemic Inflammatory Response Syndrome

BDB-001

BDB-001, BDB001, BDB 001

Phase 3 Clinical

Staidson(Beijing) Biopharmaceuticals Co Ltd

Coronavirus Disease 2019 (COVID-19), Neoplasms, Hidradenitis Suppurativa

Eculizumab biosimilar (Biocad)

BCD-148

Phase 3 Clinical

Biocad

Hemoglobinuria, Paroxysmal

Crovalimab

SKY-59, RG-6107, CH-7092230, RO-7092230, RO-7112689, RO-7112689/F01

Phase 3 Clinical

F. Hoffmann-La Roche Ltd, Chugai Pharmaceutical Co Ltd

Hemoglobinuria, Paroxysmal

Eculizumab biosimilar (IBC GENERIUM)

Phase 3 Clinical

Ibc Generium

Hemoglobinuria, Paroxysmal, Atypical Hemolytic Uremic Syndrome

Eculizumab biosimilar (Amgen)

ABP-959

Phase 3 Clinical

Amgen Inc

Hemoglobinuria, Paroxysmal, Hemolytic-Uremic Syndrome

Pozelimab

REGN-3918

Phase 3 Clinical

Regeneron Pharmaceuticals Inc

Hemoglobinuria, Paroxysmal

Eculizumab biosimilar (CinnaGen)

Phase 3 Clinical

Cinnagen

Hemoglobinuria, Paroxysmal

Nomacopan

EV-576, rVA576, rEV-576

Phase 3 Clinical

Evolutec

Myasthenia Gravis, Hemoglobinuria, Paroxysmal, Arthritis, Rheumatoid, Sjogren's Syndrome, Autoimmune Diseases, Atypical Hemolytic Uremic Syndrome, Hemolytic-Uremic Syndrome, Asthma, Keratoconjunctivitis, Inflammation, Guillain-Barre Syndrome

Eculizumab biosimilar (Samsung Bioepis)

SB-12

Phase 3 Clinical

Samsung Bioepis

Hemoglobinuria, Paroxysmal

Tesidolumab

NOV-4, LFG-316

Phase 2 Clinical

Novartis Pharma Ag, Morphosys Ag

Hemoglobinuria, Paroxysmal, Wet Macular Degeneration, Geographic Atrophy, Macular Degeneration

Olendalizumab

ALXN-1007

Phase 2 Clinical

Alexion Pharmaceuticals

Graft vs Host Disease, Antiphospholipid Syndrome, Rejection of organ transplantation, Inflammation

Cemdisiran

ALN-CC5

Phase 2 Clinical

Alnylam Pharmaceuticals Inc

Glomerulonephritis, IGA, Hemoglobinuria, Paroxysmal, Atypical Hemolytic Uremic Syndrome, Hemolytic-Uremic Syndrome

ALXN-5500

ALXN-5500

Phase 1 Clinical

Alexion Pharmaceuticals Inc

Hemoglobinuria, Paroxysmal

ALXN-1720

ALXN-1720

Phase 1 Clinical

Alexion Pharmaceuticals

Pexelizumab

Discontinued

Stanford University

Reperfusion Injury, Myocardial Infarction

What's Next for KO Library?

Please stay tuned for the latest progress of KO Library. We are open to co-development programs of antibody therapeutics using our RenMab™-target-knockout mice.
Please contact our team if you are interested in learning more about KO Library or partnering opportunities.